Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking
Thrombosis and Haemostasis · 01.09.2023 · 123 (09) · 841-854
DOI: 10.1055/a-2057-8710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2023. Verfasst von Masayoshi Souri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan. Hauptthemen laut MEDLINE: Factor XIII, Factor XIII Deficiency. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Japanese Ministry of Health, Labor, and Welfare, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Coagulation factor XIII (FXIII) is a proenzyme of plasma transglutaminase. It comprises two catalytic A subunits (FXIII-A) and two carrier B subunits (FXIII-B). We previously reported that alloantibodies against FXIII-B could promote FXIII clearance in a patient with congenital FXIII-B deficiency who had received infusions of plasma-derived human FXIII (A2B2 heterotetramer).
Objectives
We aimed to investigate whether anti-FXIII-B antibodies affect the catalytic function of FXIII.
Methods
FXIII activation and fibrin crosslinking were examined in the presence of patient plasma, isolated patient IgG, or rat anti-FXIII-B monoclonal antibodies.
Results
Alloantibody levels were increased by repeated infusions of plasma-derived A2B2 heterotetramer, which enhanced binding to the functionally important FXIII-B sushi domains. The patient plasma strongly inhibited cleavage of the FXIII-A activation peptide, amine incorporation, and fibrin crosslinking in normal plasma. Furthermore, anti-FXIII-B alloantibodies blocked the formation of the complex of FXIII-B with FXIII-A, and fibrinogen. Rat monoclonal antibodies against the 10th sushi domain of FXIII-B inhibited the incorporation of FXIII-B to fibrin, FXIII activation (i.e., cleavage of FXIII-A activation peptide), and ultimately fibrin crosslinking in normal plasma, independent of their effect on heterotetramer assembly with FXIII-A. Alloantibody binding to the A2B2 heterotetramer blocked the access of thrombin to the FXIII-A cleavage site, as indicated by the reaction of the alloantibodies to the A2B2 heterotetramer and FXIII-B, but not to FXIII-A.
Conclusion
Anti-FXIII-B antibodies binding to the A2B2 heterotetramer and FXIII-B inhibited FXIII activation and its crosslinking function despite being directed against its noncatalytic subunit (FXIII-B).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
- The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata, Japan.
- Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yonezawa, Japan.
- Department of Biochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan.
ORCID-Profile: Akitada Ichinose
Förderung
- Japanese Ministry of Health, Labor, and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Souri, M., Yokoyama, C., Osaki, T., & Ichinose, A. (2023). Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking. Thrombosis and Haemostasis, 123(09), 841-854. https://doi.org/10.1055/a-2057-8710
Vancouver
Souri M, Yokoyama C, Osaki T, Ichinose A. Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking. Thrombosis and Haemostasis. 2023;123(09):841-854. doi:10.1055/a-2057-8710
BibTeX
@article{Souri2023,
author = {Souri, Masayoshi and Yokoyama, Chikako and Osaki, Tsukasa and Ichinose, Akitada},
title = {Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {09},
pages = {841--854},
doi = {10.1055/a-2057-8710}
}
EUVIMED